PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

COMPLETE IF KNOWN	
Application Number	10/678388
Filing Date	10/03/2003
First Named Inventor	KATERINA LEFTHERIS
Art Unit	1624
Examiner Name	BALASUBRAMANIAN, VENKATARAMAN
Attorney Docket Number	QA0287B - CIP

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
VB		Branger, J., et al., "Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia", The Journal of Immunology, Vol. 168, pp. 4070-4077, (2002)	
		Davis, J. C., Jr., "Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis", Seminars in Arthritis and Rheumatism, Vol. 34, pp. 668-677, (2004)	
		Gottlieb, A. B., et al., "TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques[1]", The Journal of Immunology, Vol. 175, pp. 2721-2729, (2005)	
		Hideshima, T. et al, "Targeting p38 MAPK Inhibits multiple myeloma cell growth in the bone marrow milieu", Blood, Vol. 101(2), pp. 703-706, (2003)	
		Johansen, C., et al., "Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 2[1]", The Journal of Immunology, Vol. 176, pp. 1431-1438, (2006)	
		Johansen, C., et al., "The mitogen-activated protein kinases p38 and KRK1/2 are increased in lesional psoriatic skin", British Journal of Dermatology, Vol. 152, pp. 37-42, (2005)	
		Kumar, S., et al., "P38 MAP Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases", Vol. 2, pp. 717-726, (2003)	
		Mease, P. J., et al., "Psoriatic arthritis treatment: biological response modifiers", Ann. Rheum. Dis., Vol. 64 (Suppl. II), pp. ii78-ii82, (2005)	
		Navas, TA, et al., "Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X_L, MCl-1 and p53 levels *in vitro* and inhibits tumor growth *in vivo*, Leukemia, 1-11 (2006)	
		Papp. K. A., "The long-term efficacy and safety of new biological therapies for psoriasis", Arch. Dermatol. Res. Vol. 298, pp. 7-15, (2006)	
		Saklatvala, J., "The p38 MAP kinase pathway as a therapeutic target in inflammatory disease", Current Opinion in Pharmacology, Vol. 4, pp. 372-377, (2004)	
VB		Waetzig G. H., "p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease[1]", The Journal of Immunology, Vol. 168, pp. 5342-5351, (2002)	

Examiner Signature	V Balasubramanian	Date Considered	9/23/09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

OIPE
AUG 0 2 2006
PATENT & TRADEMARK OFFICE

PTO/SB/08A (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S)

(use as many sheets as necessary)

Sheet	1		1

COMPLETE IF KNOWN	
Application Number	10/678388
Filing Date	10/03/2003
First Named Inventor	KATERINA LEFTHERIS
Art Unit	1624
Examiner Name	BALASUBRAMANIAN, VENKATARAMAN
Attorney Docket Number	QA0267B - CIP [1]

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Check box if English language translation is attached
VB		WO 03/091229	06/11/2003	Bristol Myers Squibb Co.		☐
VB		WO 2004/043912	5/27/2004	Bristol Myers Squibb Co.		☐
VB		WO 02/40486 A2	05/23/2002	Bristol-Myers Squibb Co.		☐
						☐
						☐
						☐
						☐
						☐

Examiner Signature	V Balasubramanian	Date Considered	9/23/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant